ONCOLYTICS BIOTECH INC (ONCY) — research page

US · us-cm-kg/NASDAQ/ONCY · as of 2026-11-08

Identity and listing

The issuer is ONCOLYTICS BIOTECH INC, listed on NASDAQ under ticker ONCY, with ISIN US68237V1035. The LEI is not on the record, as no GLEIF record carries the exact legal name in jurisdiction US-NV. The security type is Corporate, the segment is not on the record, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is United States, Nevada. The listing status is listed, not halted.

The disclosure read

The record holds 137 filings in the window 2025-11-08 to 2026-11-08, across 49 filing days. The median gap between filing days is 6.0 days. The latest filing is dated 2026-11-04, a corporate_news filing, 4 days before the record date of 2026-11-08. The NASDAQ peer median is 6.0 days of cadence, 52 filings and 5.0 days of latency across 4359 issuers. The 2834 Pharmaceutical Preparations sector peer median is 6.0 days of cadence, 63.0 filings and 4.0 days of latency across 526 issuers. The issuer's 137 filings are above the NASDAQ peer median of 52 and above the sector peer median of 63.0.

window 2025-11-08 to 2026-11-08 · the node's disclosure lines, as get_filings serves them

Auditor

The auditor of record is Ernst & Young LLP, located in Calgary, Canada. The record holds one auditor change, dated 2026-07-08.

Events and halts

The record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag is clear: listed, not halted.

Orderability

The outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, with the chapter as of 2026-11-04.

rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability

Coverage

Six research houses are named on the issuer's own investor-relations page: H.C. Wainwright, JonesTrading, Lake Street Capital Markets, Leede Financial, Maxim Group and RBC Capital Markets.

Open research

No openly published research notes are on the record. None was found.

Licensed

Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.

As-of depth

The record holds sealed filings for the issuer in the years 2021, 2022, 2023, 2024, 2025 and 2026. The market's vintage is sealed, with the earliest sealed date 2021-01-04. The live record began on 2026-09-12.

Sources

9 source pages are named on this page; every value above carries its own source page and read date in the numbers.

10.1

https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)

10.2

https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)

10.3

https://data.sec.gov/submissions/CIK0001129928.json (identity.jurisdiction)

10.4

https://mcp.us-cm-kg.ai/events/NASDAQ/ONCY (the disclosure lines)

10.5

https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)

10.6

https://www.sec.gov/Archives/edgar/data/1129928/000112992826000020/oncy-20251231.htm (the auditor)

10.7

https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)

10.8

https://ir.oncolyticsbiotech.com/investor-overview/stock-information/ (coverage)

10.9

https://mcp.us-cm-kg.ai/record/NASDAQ/ONCY (the record)

Read it by agent

The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"US68237V1035"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:8585bb030f809a2a.